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Abstract 
Two series of experiments (in vivo and in vitro) were performed to determine protective level of antibodies to tick-
borne encephalitis virus (TBEV). We considered, basing on the data of neutralization tests (one TBEV doze (3 lg 
TCID50) with different titers of specific IgG antibodies (from 1:6400 to 1:12.5)) that antibody titer 1:400 in enzyme-
linked immunosorbent assay (ELISA) and 1:20 in neutralization test (NT) is a minimal threshold of protective level, 
and 1:100 – a lower threshold of immunological memory. During the second series of experiments on neutralization 
of different TBEV titers (from 1 to 8 lg TCID50) with immunoglobulin (antibody titers 1:400 and 1:3200) we 
obtained the additional evidence that high IgG titers (1:3200) actively neutralized TBEV, and antibody titer 1:400 
was the lower threshold of protection. This characteristic was used to assess an immunological effectiveness of 
vaccine Encepur® adult. After three years of a full vaccination course we observed high values of a specific 
immunity, and after five years, in half of the cases revaccination was required. 
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1. Introduction 
World experience have proved that vaccination is the most reliable and effective protection against 
viral infections. The practical use of vaccines against TBEV produced by different manufacturers shows 
that the most effective means for TBE prevention in highly endemic regions is vaccination of residents [1, 
2]. 
 
A high-purified Encepur® vaccine is used for about ten years for TBEV prevention in Russia. 
Although this vaccine is prepared from the strain K23 (Western TBEV subtype), it is highly 
 
* Corresponding author. Tel.:+7-4232-44-07-12; fax:+7-4232-44-11-47. 
E-mail address: galinaleon@mail.primorye.ru 
 Leonova / Procedia in Vaccinology  00 (2011) 000–000 
immunogenic against Far Eastern subtype of TBEV [3]. So far, cases of TBE infection among individuals 
vaccinated with Encepur® were not registered both in Europe and in Russia.  
 
The easiest and most effective way to determine the level of a specific immune response in individuals 
vaccinated against TBEV is ELISA. It allows determining a specific anti-TBEV IgG titer. We identified 
that anti-TBEV antibody in some individuals remains for a long time despite a decrease of immune 
response characteristics [4]. We tried to obtain the experimental evidence for a protective ability of 













2. Materials and methods 
2.1. Study design and population 
To analyse the protective titer of specific antibodies, we performed two sets of in vitro experiments 
using the anti-TBEV immunoglobulin (serial number 521207, State Healthcare Institution 
"Sverdlovskaya OSPK" (regional hemotransfusion station, Pervouralsk, Russia). Samples was prepared 
by mixing an equal volumes of  TBEV (3 lg according to 50% tissue culture infective dose, TCID50) and a 
specific immunoglobulin in two-fold dilutions with titers from 1:10 to 1:3200.  The time of exposure of 
the virus (strain P-73) with immunoglobulin against TBE was 15 min. The experiment was repeated 3 
times.  
 
We compared the immune response of 10 selected volunteers after threefold Encepur® adult 
vaccination within 2 periods: 3 and 5 years later.  
2.2. Virus strain 
We used previously described Far Eastern TBEV strain P-73 (GenBank accession # DQ667008). The 
strain was isolated from the brain of the patient with the focal form of infection. 
2.3. Methods 
IgG antibodies were determined by ELISA using a "Vecto-TBE-IgG" kit (JSC "Vector-Best", 
Novosibirsk, Russia) according to the manufacturer’s instructions. Enzyme immunoassay of avidity was 
conducted according to [5]; antibodies with the avidity index below 30% were regarded as low-avidity, 
from 31 to 50% – medium-avidity, and over 51% – high-avidity ones. 
 
For NT one-day-old monolayer of continuous pig kidney embryo (PKE) cells in 24-well plates was 
infected with the regional P-73 TBEV strain at a working dose of 2 lg TCID50. Virus-neutralizing 
antibody titers was determined with two-fold dilutions of the studied blood sera (the initial dilution 1:10). 
Nomenclature 
TBEV Tick-borne encephalitis virus  
ELISA  Enzyme-linked immunosorbent assay 
NT Neutralization test 
PKE       Pig kidney embryo cell culture 
TCID50  50% tissue culture infective dose 
LD50       50% lethal dose 
AI           Avidity index  
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immunogenic against Far Eastern subtype of TBEV [3]. So far, cases of TBE infection among individuals 
vaccinated with Encepur® were not registered both in Europe and in Russia.  
 
The easiest and most effective way to determine the level of a specific immune response in individuals 
vaccinated against TBEV is ELISA. It allows determining a specific anti-TBEV IgG titer. We identified 
that anti-TBEV antibody in some individuals remains for a long time despite a decrease of immune 
response characteristics [4]. We tried to obtain the experimental evidence for a protective ability of 
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In the second set of experiments, anti-TBEV immunoglobulin (IgG titers 1:400 and 1:3200) were 
mixed with TBEV in doses from 1 to 8 lg LD50. Residual virus titer was determined by titration in PEK 
cells and white mice, the presence of antigen and TBEV RNA was controlled by ELISA and RT-PCR, 
respectively.  
2.3.1. Virus detection  
TBEV antigen was determined in ELISA using immune-enzyme test system "Vecto-TBE-antigen-
strip" (JSC "Vector-Best, Novosibirsk, Russia). Results were recorded by optical density (OD) in the 
spectrophotometer at 450 nm. According to manufacturer’s instruction to interpret the results, we 
introduced a threshold value (a critical OD value – ODcritical): the mean OD in wells for negative control 
(ODNegative controlm) was calculated. Then, ODcritical was calculated as:     
 
ODcritical = ODNegative controlm + 0.1                                                                                                     (1) 
 
Test was positive, if the OD in wells was higher than ODcritical: 
 
The positiveness coefficient (K) = ODtest sample/ODcritical                                                                                                      (2) 
 
K threshold value was higher than 1.0. 
2.3.2. Polymerase chain reaction 
We also used reverse-transcription – polymerase chain reaction (RT-PCR). RNA was extracted using 
RIBO-zol kit ("AmpliSens", Moscow, Russia) according to the manufacturer's instruction. cDNA was 
synthesized by reverse transcription using "REVERTA-100" kit ("AmpliSens", Moscow, Russia) 
according to the manufacturer's instruction. PCR was performed using "AmpliSens" reagents (Moscow, 
Russia). Amplification products were analyzed by electrophoresis in 1.5% agarose gel.  
2.3.3. Virus titration 
Residual infectivity was tested in PEK cell culture by treatment of 10-fold dilutions of samples and 
evaluated in TCID50. 
3. Results 
3.1. Experimental studies  
Within the first set of experiments (TBEV mixed with IgG in different dilutions), we pointed out the 
sample with IgG titer 1:400. Fig. 1 shows that antibodies in this sample were completely bounded to the 
virus. Values of K in ELISA (antigene detection) were ambiguous during the experiments: for samples 
with high IgG titers (1:6400 and 1:1600) K was above the threshold (3.9 and 1.6 respectively), then it 
decreased up to 0.4. However, with the further decrease of IgG titers these characteristics increased up to 
the positive value (1.0).  
 
The RT-PCR results were positive for all samples. The occurrence of a free infectious virus of 0.9 and 
1.0 TCID50 was an evidence of unfavourable conditions for a specific protection in samples with IgG titer 
less than 1:100. Similar results were obtained by NT (Table), the minimal threshold of protection was 





























Fig. 1. Initial IgG titer (1), decreasing of IgG titer (2), decreasing of antigene titer (3), neutralization of TBEV 3 lg TCID50 (4) in 
samples with serial 2-fold IgG dilutions 
 
Table. Experimental substantiation of protective IgG titer threshold under the influence of TBEV exposure (3 lg TCID50) based on 

















To confirm the obtained data, we performed a second set of experiments (in vivo and in vitro). TBEV 
doses from 1 to 8 TCID50 was compared in neutralization with immunoglobulin (titers 1:3200 and 1:400). 
Titration in PKE cells (fig. 2A) showed that IgG (titer 1:400) entirely neutralized 3 lg TCID50 of TBEV as 
well as in the first set of experiments, and IgG (titer 1:3200) neutralized 4 lg TCID50. Moreover, initial 
virus titer (5-6 lg TCID50 or 7-8 lg TCID50) after IgG  treatment (titer 1:3200) was reduced by 3-4 lg 
TCID50 or 1-2 lg TCID50 respectively. 
















6400 1600 320 80 3,8  0 + 
3200 800 160 80 1,6  0 + 
1600 400 80 80 0,8  0 + 
800 200 40 40 0,5  0 + 
400 0 20 20 0,4  0 + 
200 0 10 0 1.0 0 + 
100 0 5 0 0,8  0 + 
50 0 2,5 0 0,7  0,9 + 
0 0 1,22 0 0,9  1,0 + 
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Fig. 2. IgG protectivity at titers 1:400 (1) and 1:3200 (2) against TBEV (1-8 lg TCID50(A)/LD50(B)) 
A – PKE cells (in vitro)  B – white mice (in vivo) 
Tiration on mice (Fig. 2B) showed  that IgG (1:400) entirely neutralized TBEV at 3 lg LD50, decreased 
TBEV titer by 3-4 lg LD50 from initial 4, 5, 6 lg LD50, but was unable to neutralize 7 and 8 lg LD50. IgG 
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with titer 1:3200 entirely neutralized 5 lg LD50 and decreased TBEV titer of 6, 7 and 8 lg LD50 by 5.5 lg 
LD50, 3 lg LD50, and 2 lg LD50 of TBEV, respectively. 
 
According to our data on neutralization of different IgG antibody titers with one dose of TBEV (3 lg 
TCID50) we considered a lower threshold of antibody protective level is to be 1:400 in ELISA and 1:20 in 
NT. The second set of experiments confirmed that in ELISA an IgG titer 1:400 should be considered as 
the lower threshold of antibody protective level and this threshold can be used for assessment of 
immunological effectiveness of vaccines used for TBEV prevention.  
3.2. Assessment of immunological effectiveness of vaccine Encepur® adults 
We assessed immunological effectiveness of vaccine Encepur® adults in remote periods after a full 

























Fig. 3. The level of specific antibodies of individuals immunized by Encepur® adult 
1 – IgG level 3 years after immunization; 
2 – IgG level 5 years after immunization; 
3 – antibody avidity 3 years after immunization; 
4 - antibody avidity 5 years after immunization 
Х axis – sample number  
Y-1 axis (left) – IgG titer via ELISA, Y-2 axis (right) – IgG titer via NT 
 
We analyzed blood serums of individuals (n=10) three and five years after the vaccination. ELISA 
results (Fig. 3) shows that IgG titers in these individuals were high for three years after of full course of 
vaccination: 1:3200 – six cases, 1:1600 – one case, 1:800 – one case and 1:400 – two cases. The avidity 
index of these antibodies was high or average. Five years after the characteristics of immune response 
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decreased: IgG 1:3200 remained in three cases, 1:1600 – two cases, 1:800 – two cases, 1:400 – two cases 
and 1:200 – in one case. The avidity index decreased too: it was average in five cases and low in other 
five. 
4. Discussion
The notion of protective antibody titer appeared during the studies on estimation of vaccinal 
immunological activity. Preventive vaccines effectiveness against some infection was considered to be 
assessed by the protective level of immunological characteristics [6]. In 1980th Kunz et al. [7] considered 
that the protective titer of hemagglutinating antibodies for TBEV vaccine is above 1:10. At present time 
the most of diagnostic laboratories use ELISA as the main standard detection method of specific IgG 
antibodies. The goal of the present study is to estimate the protective IgG titer for individuals vaccinated 
against TBEV. 
 
For the first time we obtained an evidences for the lower threshold of protective IgG titer in different 
variations of experiments. Thus, at the virus dose of 3 lg TCID50 the protective effect of IgG was detected 
from the titer 1:6400 to 1:100. Cytopathic effect was not registered in the culture of PKE cells infected 
with these samples. We considered the lower threshold of protective IgG activity is 1:400 according to 
ELISA data, and 1:20 according to NT. Although this sample was positive in RT-PCR, we did not 
identify virus antigen in ELISA, and antibodies in the examined sample eliminated completely. With the 
further decrease of antibody titer, we observed an increase in characteristics of K values in antigen-
detection ELISA and a free infective virus up to 1lg TCD50 appears in the samples with IgG titer lower 
than of 1:100 (ELISA data). Due to this fact we considered that antibody titer of 1:100 can not be called a 
threshold of protective level as it was reported by [8], but a lower threshold of immunological memory 
enabling further vaccination. Individuals vaccinated against TBE with antibody titer of 1:100 in blood can 
avoid an illness after the tick bite if they receive a relatively low virus dose. However, the possibility of 
TBE infection still remains. Moreover, some cases of severe nervous system damage occurs among 
immunized individuals in addition to febrile forms of disease. 
 
Moreover, high IgG titers (1:3200) actively neutralized TBEV and were probably able to ensure a 
safeguard against this disease. The second series of comparative experiments on neutralization of 
different quantities of TBEV (from 1 to 8 lg) with IgG titer of 1:400 and initial antibody titer of 1:3200 
gave the additional evidence that IgG titer 1:400 is a minimal level of protective antibody activity. These 
data can be used at any time of observation after vaccination of the patients to assess the immunological 
effectiveness of vaccines used for TBEV prevention. Antibody titers equal to 1:400 and lower indicate the 
necessity of revaccination.    
 
Taking into account the experimental data, we analyzed the individual immune response of ten 
individuals vaccinated with Encepur® adult three and five years after a course of three vaccine injections. 
We determined that this vaccine enables long time production of antibodies which remains for up to five 
years (observation time). As a rule, repeated vaccination contributes to formation of high-avidity 
antibodies [9] which usually have high affinity to specific antigen sites and are able to eliminate antigen 
actively. A considerable part of immune sera of vaccinated individuals contained avid antibodies with 
high avidity index (AI) three years after a full course of vaccination, and moderate AI after five years. It 
reached an average level in the half of the cases, and low level in the rest. In other words, individuals with 
antigen titer of 1:400 and lower, as well as those with low avidity should be revaccinated five years after 
a full course of vaccination. This approach to periods of vaccination was confirmed by the work of Heinz 
FX et al. [4], who recommended revaccinations for all individuals vaccinated against TBEV, and after 
five years revaccination was not recommended only for the aged individuals.  
 
Therefore, the data obtained on the threshold of antibody titer (1:400) and determination of a minimal 
level of their immunological memory (1:100) helps to determine an immunological protectiveness of the 
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vaccinated individuals and duration of postvaccinal protective immunity and, thus, specify revaccination 
schedule. To obtain the maximal immunological and epidemiological effectiveness of vaccinal prevention 
against TBEV, individual approach to each patient is appropriate. Moreover, it may have medical and 
economic importance. 
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against TBEV. 
 
For the first time we obtained an evidences for the lower threshold of protective IgG titer in different 
variations of experiments. Thus, at the virus dose of 3 lg TCID50 the protective effect of IgG was detected 
from the titer 1:6400 to 1:100. Cytopathic effect was not registered in the culture of PKE cells infected 
with these samples. We considered the lower threshold of protective IgG activity is 1:400 according to 
ELISA data, and 1:20 according to NT. Although this sample was positive in RT-PCR, we did not 
identify virus antigen in ELISA, and antibodies in the examined sample eliminated completely. With the 
further decrease of antibody titer, we observed an increase in characteristics of K values in antigen-
detection ELISA and a free infective virus up to 1lg TCD50 appears in the samples with IgG titer lower 
than of 1:100 (ELISA data). Due to this fact we considered that antibody titer of 1:100 can not be called a 
threshold of protective level as it was reported by [8], but a lower threshold of immunological memory 
enabling further vaccination. Individuals vaccinated against TBE with antibody titer of 1:100 in blood can 
avoid an illness after the tick bite if they receive a relatively low virus dose. However, the possibility of 
TBE infection still remains. Moreover, some cases of severe nervous system damage occurs among 
immunized individuals in addition to febrile forms of disease. 
 
Moreover, high IgG titers (1:3200) actively neutralized TBEV and were probably able to ensure a 
safeguard against this disease. The second series of comparative experiments on neutralization of 
different quantities of TBEV (from 1 to 8 lg) with IgG titer of 1:400 and initial antibody titer of 1:3200 
gave the additional evidence that IgG titer 1:400 is a minimal level of protective antibody activity. These 
data can be used at any time of observation after vaccination of the patients to assess the immunological 
effectiveness of vaccines used for TBEV prevention. Antibody titers equal to 1:400 and lower indicate the 
necessity of revaccination.    
 
Taking into account the experimental data, we analyzed the individual immune response of ten 
individuals vaccinated with Encepur® adult three and five years after a course of three vaccine injections. 
We determined that this vaccine enables long time production of antibodies which remains for up to five 
years (observation time). As a rule, repeated vaccination contributes to formation of high-avidity 
antibodies [9] which usually have high affinity to specific antigen sites and are able to eliminate antigen 
actively. A considerable part of immune sera of vaccinated individuals contained avid antibodies with 
high avidity index (AI) three years after a full course of vaccination, and moderate AI after five years. It 
reached an average level in the half of the cases, and low level in the rest. In other words, individuals with 
antigen titer of 1:400 and lower, as well as those with low avidity should be revaccinated five years after 
a full course of vaccination. This approach to periods of vaccination was confirmed by the work of Heinz 
FX et al. [4], who recommended revaccinations for all individuals vaccinated against TBEV, and after 
five years revaccination was not recommended only for the aged individuals.  
 
Therefore, the data obtained on the threshold of antibody titer (1:400) and determination of a minimal 
level of their immunological memory (1:100) helps to determine an immunological protectiveness of the 
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vaccinated individuals and duration of postvaccinal protective immunity and, thus, specify revaccination 
schedule. To obtain the maximal immunological and epidemiological effectiveness of vaccinal prevention 
against TBEV, individual approach to each patient is appropriate. Moreover, it may have medical and 
economic importance. 
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